Re-examining our approach to the approval and use of new drugs

Lee, Shoo K.
June 2006
CMAJ: Canadian Medical Association Journal;6/20/2006, Vol. 174 Issue 13, p1855
Academic Journal
Discusses several researches concerning the approval and use of new drugs. Risks associated with the use of L-lysine ibuprofen therapy for patent ductus arteriosus; Inefficiency of clinical drug trials in detecting adverse drug reactions; Percentage of drugs approved by the U.S. Food and Drug Administration that acquired a black box warning.


Related Articles

  • US court rules to allow experimental drugs for dying patients. Waltz, Emily // Nature Medicine;Jun2006, Vol. 12 Issue 6, p596 

    The article reports that a U.S. federal appeals court has ruled that people dying from a terminal illness have the right to buy experimental drugs from companies before the Food and Drug Administration has approved them. The ruling could bring hope to people desparately trying to extend their...

  • Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. Peytavin, G.; Gautran, C.; Otoul, C.; Cremieux, A. C.; Moulaert, B.; Delatour, F.; Melac, M.; Strolin-Benedetti, M.; Farinotti, R. // European Journal of Clinical Pharmacology;Jun2005, Vol. 61 Issue 4, p267 

    Background: Serious adverse effects have been observed with some non-sedative H1-antihistamines (terfenadine and astemizole) when they were associated with drugs known to inhibit their metabolism. However, this is not a class effect, and this interaction should be considered on a case-by-case...

  • Valproic acid interaction.  // Reactions Weekly;9/16/2006, Issue 1119, p21 

    The article discusses research being done on valproic acid. It references a study by S. Fudia published in the August 2006 issue of the "Journal of Clinical Pharmacy and Therapeutics." A woman who experienced post-surgical epileptic seizures was given valproic acid. She developed pneumonia...

  • Firm stops trials of obesity drug.  // GP: General Practitioner;11/14/2008, p4 

    The article reports on the decision of Sanofi-Aventis to discontinue all trials of its anti-obesity drug rimonabant called Acomplia. It notes that the drug was suspended by the European Medicines Agency (EMEA) after an assessment of Acomplia's benefits and risks showed an increased risk of...

  • Clinuvel Filing for Scenesse in Eu on Phase III Data in EPP. Sheridan, Cormac // BioWorld International;12/21/2011, Vol. 16 Issue 51, p1 

    The article reports on the plan of Clinuvel Pharmaceuticals Ltd. to complete a European regulatory filing for its lead drug Scenesse (afamelanotide) after a Phase III trial in patients with erhythropoietic protoporphyria (EPP). EPP arises from a deficiency in ferrochelatase. Information on...

  • PHARMACY CORNER. Fieler, Vickie K. // Oncology Nursing Forum;Jul2005, Vol. 32 Issue 4, p867 

    Presents an update on drugs developed for the treatment of cancer as of July 2005. Adverse reactions of GlaxoSmithKline' ondansetron to the pediatric patients included in its study; Effect of the orphan drug status given to Rexahn's RX-0201 on its approval; Changes in the formulation of...

  • Rosiglitazone and implications for pharmacovigilance. Kazi, Dhruv // BMJ: British Medical Journal (International Edition);6/16/2007, Vol. 334 Issue 7606, p1233 

    This editorial examines the use of rosiglitazone or Avandia in the treatment of diabetes and the studies that suggest its use is associated with an increased risk of heart failure. The author states that postmarketing drug surveillance, or pharmacovigilance, is the weakest link of the drug...

  • Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. Fletcher, A. P. // Journal of the Royal Society of Medicine;Jun1991, Vol. 84 Issue 6, p341 

    Spontaneous adverse drug reaction (ADR) reporting is the mainstay of national and international drug safety evaluation in the post-approval phase. A major criticism of the method has been a high, but essentially unquantifiable, level of under-reporting by doctors. A direct comparison has been...

  • Sport, lies and steroids.  // New Scientist;8/14/2004, Vol. 183 Issue 2460, p3 

    The article focuses on a study into effects of testosterone on the performance of amateur athletes. Critics say that this kind of study is pointless, because high-profile cases of top athletes being caught cheating already show that drugs work. The side effects observed were minimal, but the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics